Clinical Trial

Research of Nicotine Addiction

Study Description

Translational Neuropsychopharmacology Research of Nicotine Addiction

This study will examine the effects of combining Varenicline (VRN) and N-acetylcysteine (NAC) on neural circuitry function and treating nicotine addiction. Healthy adult nicotine dependent cigarette smokers interested in quitting (n=110) will be randomized to one of four PBO-controlled conditions for 4 weeks: 1) VRN+NAC, 2) VRN+PBO, 3) NAC+PBO or 4) PBO+PBO. Following 1 week of medication, participants will be contingently reinforced for 3 days of smoking abstinence and be scanned using functional magnetic resonance imaging (fMRI) techniques, while nicotine deprived during a resting state and a cue-reactivity (CR) task. Participants will be followed over the next 3 weeks of treatment and clinical variables will be assessed.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Varenicline (VRN)

VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.

Drug - N-Acetylcysteine (NAC)

NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment

Drug - Placebo

Matched placebo

Additional Information

Official Study Title

Translational Neuropsychopharmacology Research of Nicotine Addiction

Clinical Trial ID

NCT02723162

ParticipAid ID

QeZXgb